Vioxx: an unequal partnership between safety and efficacy

@article{Lancet2004VioxxAU,
  title={Vioxx: an unequal partnership between safety and efficacy},
  author={The Lancet},
  journal={The Lancet},
  year={2004},
  volume={364},
  pages={1287-1288}
}
  • T. Lancet
  • Published 15 October 2004
  • Medicine
  • The Lancet
13 Citations
Pharmacovigilance as a Tool for Ensuring Economic Security in the Russian Healthcare System
–The article shows the role of the pharmacovigilance system for ensuring the economic security of the state by preventing and minimizing adverse reactions (ADRs) and side effects arising from the use
Post-marketing withdrawal of analgesic medications because of adverse drug reactions: a systematic review
TLDR
Greater co-ordination across regulatory authorities in assessing and interpreting the benefit-harm balance of new analgesics should be encouraged and future reporting of harms in clinical trials of analgesic should follow standardized guidelines.
Policy Issues for the Development and Use of Biomarkers in Health
TLDR
The report presents several policy options which could foster biomarker research, discovery, development, commercialisation and uptake in clinics and identifies the barriers which may slow or block the uptake and diffusion of biomarker-based technologies in the clinical setting.
Association between biologic therapies for chronic plaque psoriasis and cardiovascular events: a meta-analysis of randomized controlled trials.
TLDR
There was no significant difference in the rate of MACEs observed in patients receiving anti-IL-12/IL-23 antibodies or anti-TNF-α treatments in adults, and this study may have been underpowered to identify a significant difference.
The financial and market impact of catastrophic product failure
On September 30th of 2004, Merck & Co. Inc. made the rather surprising announcement that it was withdrawing Vioxx due to its increased cardiovascular risk. The withdrawal of Vioxx was surely a
Efficacy and tolerability of lumiracoxib 100 mg once daily in knee osteoarthritis: a 13-week, randomized, double-blind study vs. placebo and celecoxib
TLDR
Lumiracoxib 100 mg od provided effective relief from the pain of knee OA, with efficacy similar to celecoxib 200‬mg od, and was well tolerated.
Mechanisms of Disease: prostate cancer—a model for cancer chemoprevention in clinical practice
TLDR
Development of an effective chemoprevention strategy for prostate cancer is evolving and will likely serve as a model for chemoplevention of other adult malignancies.
Prescribers and drug withdrawals
The much publicised withdrawal of rofecoxib and the subsequent queries about the safety of celecoxib evoked a huge response in both the lay and the medical press.
Utilisation of Non-steroidal Anti-inflammatory Drugs (NSAIDs) through Community Pharmacies in Malaysia
TLDR
Elderly respondents were more likely to be dispensed a selective COX-2 inhibitor than those below 60 and NSAIDs were recommended based mainly on the pharmacist's perception of their efficacy, cost and safety.
...
1
2
...